Rocky Mountain Advisers, LLC G1 Therapeutics, Inc. Transaction History

Rocky Mountain Advisers, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$4.04 - $8.51 $2,020 - $4,255	-500 Reduced 22.22%	1,750 $9,000
Q1 2022 Apr 27, 2022	SELL	$7.6 - $11.02 $760 - $1,102	-100 Reduced 4.26%	2,250 $17,000
Q4 2021 Feb 09, 2022	SELL	$10.16 - $16.17 $5,842 - $9,297	-575 Reduced 19.66%	2,350 $24,000
Q2 2020 Jul 27, 2020	BUY	$9.57 - $24.37 $6,459 - $16,449	675 Added 30.0%	2,925 $71,000
Q1 2020 Apr 29, 2020	BUY	$9.07 - $26.32 $20,407 - $59,220	2,250 New	2,250 $25,000

3.55M

11.7K

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

Get notified when there are updates to the investment portfolio of Rocky Mountain Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Rocky Mountain Advisers, LLC with notifications on news.